Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
about
New anticoagulants for the prevention and treatment of venous thromboembolismSynthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.Beyond heparin and warfarin: the new generation of anticoagulants.Heparin oligosaccharides as potential therapeutic agents in senile dementiaRecent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors.Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.Factor X inhibitors.New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinThe safety of fondaparinux for the prevention and treatment of venous thromboembolism.Short- and long-acting synthetic pentasaccharides as antithrombotic agents.The status of new anticoagulants.Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implicationsClinical efficacy and safety of fondaparinux in the prevention and treatment of venous and arterial thrombosis.Newer anticoagulants in 2009.Laboratory assessment of new anticoagulants.PK evaluation of fondaparinux sodium for the treatment of thrombosis.Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications.The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines.Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury.
P2860
Q24681351-7F0810DA-E1B8-4A2B-A95D-E43047D0F460Q33331831-6DDC973E-ED7B-4E27-8752-CE093EB7E700Q33374258-A0447FF4-FE84-4D67-91DE-D8FAA1DB87BAQ33965772-2F4F205D-33D7-4D96-BCB7-595E347855BEQ34074963-61EE38F9-CF6C-411E-98F4-8C38479D5C49Q34549913-CBE5F93C-4269-49DB-A1AF-611440ACD06CQ35117073-71C1CCB0-73D6-4D9D-AD2C-15603B03677CQ36042279-BA56B143-43DF-428C-ABA7-5CB9A342A69EQ36191034-D8DB68D1-9EDA-4125-A0A9-CD1501504CFEQ36196467-59E45DC9-ABE2-4305-A8D6-B9CAF15EB930Q36520745-FDAA6E96-77CE-48E6-A84B-B7C2A3011813Q37142019-97EFB943-3088-4EA5-840C-434460E18006Q37193906-4B7831D2-1763-41E6-88BA-035E26AEA113Q37608455-E405A436-67AD-4A3E-8385-C82B49A1D4EDQ37617159-51D53A5D-F188-460B-BEDD-309DB595C88DQ37834646-FA7815FD-4133-476E-84D6-FD7069C7636AQ38173014-DFED153A-F513-4FFA-92E6-E8E6C93B5086Q38303999-EBB51D32-39E4-4A7A-8953-2CC1D3B9C43AQ39252361-83FB31FB-C2B1-4ECC-85E2-3441A283F4AEQ44678432-14229BE8-BFC3-4C9D-B877-369FE4AE4C85Q45063451-BC2706CD-EE5E-4708-8944-C71A40F06597Q45302084-A538449E-4210-41C2-9CB4-2D0E6F123903
P2860
Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Biochemical and pharmacologic ...... hetic heparin pentasaccharide.
@en
type
label
Biochemical and pharmacologic ...... hetic heparin pentasaccharide.
@en
prefLabel
Biochemical and pharmacologic ...... hetic heparin pentasaccharide.
@en
P2093
P1433
P1476
Biochemical and pharmacologic ...... hetic heparin pentasaccharide.
@en
P2093
P356
10.1016/S0049-3848(97)00042-X
P577
1997-04-01T00:00:00Z